Ken Griffin’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-17,700
| Closed | -$170K | – | 16022 |
|
|
2024
Q4 | $170K | Sell |
17,700
-30,600
| -63% | -$160K | ﹤0.01% | 10692 |
|
|
2024
Q3 | $138K | Sell |
48,300
-86,400
| -64% | -$267K | ﹤0.01% | 10676 |
|
|
2024
Q2 | $393K | Buy |
134,700
+41,700
| +45% | +$114K | ﹤0.01% | 8561 |
|
|
2024
Q1 | $297K | Buy |
+93,000
| New | +$310K | ﹤0.01% | 9474 |
|
|
2023
Q4 | – | Sell |
-21,200
| Closed | -$50.5K | – | 15457 |
|
|
2023
Q3 | $50.5K | Sell |
21,200
-26,700
| -56% | -$56K | ﹤0.01% | 11752 |
|
|
2023
Q2 | $84.3K | Buy |
47,900
+10,200
| +27% | +$26.1K | ﹤0.01% | 11180 |
|
|
2023
Q1 | $116K | Buy |
37,700
+12,300
| +48% | +$73.7K | ﹤0.01% | 11051 |
|
|
2022
Q4 | $135K | Buy |
25,400
+8,000
| +46% | +$36.6K | ﹤0.01% | 10776 |
|
|
2022
Q3 | $61K | Buy |
+17,400
| New | +$57.5K | ﹤0.01% | 11493 |
|
|
2022
Q2 | – | Sell |
-10,200
| Closed | -$46K | – | 14351 |
|
|
2022
Q1 | $46K | Buy |
+10,200
| New | +$46K | ﹤0.01% | 12850 |
|
|
2021
Q4 | – | Sell |
-11,300
| Closed | -$82K | – | 14973 |
|
|
2021
Q3 | $82K | Buy |
+11,300
| New | +$97K | ﹤0.01% | 13056 |
|
|
2021
Q2 | – | Sell |
-12,600
| Closed | -$120K | – | 14602 |
|
|
2021
Q1 | $120K | Buy |
+12,600
| New | +$124K | ﹤0.01% | 12300 |
|
Other funds holding PSTX
Ken Griffin's PSTX Position: Q1 2025 in Review
Ken Griffin sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2025, closing a stake of 154,764 shares — an estimated $1.49M sold.
Ken Griffin first reported a position in PSTX in Q3 2020 and held it in 13 quarters. The position peaked at $1.49M in Q4 2024. 1 fund tracked by Wall St. Rank holds PSTX as of Q1 2025.
- Ken Griffin reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
- Ken Griffin sold 154,764 Poseida Therapeutics, Inc. Common Stock shares in Q1 2025, an estimated $1.49M.
- Ken Griffin first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2020 and held it in 13 quarters.
- Ken Griffin's Poseida Therapeutics, Inc. Common Stock position peaked at $1.49M in Q4 2024.
- 1 fund tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2025.
Based on Citadel Advisors's 13F filing for Q1 2025, filed 15 May 2025.